Pune-based biotech startup Ahammune Biosciences has successfully raised $5 million in Series A funding, led by pi Ventures, to further its mission of developing innovative treatments for skin diseases. Other participants in the funding round included Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, and existing investors such as Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and IAN.
The new funding will enable Ahammune to conduct Phase II human clinical trials for its promising drug candidate targeting vitiligo, a skin depigmentation disorder that currently lacks a cure. Additionally, the funds will support the expansion of the company’s patent portfolio and enhance its research and development efforts for other immune-mediated skin conditions.
Since its inception, Ahammune has focused on addressing unmet medical needs in chronic skin diseases. The company is backed by a distinguished advisory board with extensive expertise in drug discovery and development.
Ahammune’s lead program aims to develop a groundbreaking drug candidate for vitiligo. Co-Founder Dr. Parul Ganju highlighted the unique attributes of their drug: “Unlike existing treatments, our small molecule drug candidate does not cause generalized immunosuppression and has a first-in-class mechanism of action. It can not only halt patch spread but also stimulate the function of pigment-producing cells in the skin, leading to repigmentation. We have established its safety in Phase I clinical trials with healthy subjects, and as a topical application, it holds the potential to significantly improve the lives of millions affected by this lifelong condition. We are now moving forward with Phase II trials to assess safety and efficacy in vitiligo patients.”
In addition to its work on vitiligo, Ahammune is developing a robust pipeline of patented molecules aimed at treating various dermatological and autoimmune diseases.
4o mini
